肺炎链球菌的万科米辛耐药性,一个案例报告
Zana Baqi Najmadden1, Khalid Hama Salih2, Jihad Ibrahim Hama1
1University of Halabja, Halabja, Kurdistan Region, Iraq.
Sage open pediatrics..
|July 4, 2025
概括
在伊拉克的一名9个月大的婴儿身上发现了一种罕见的抗万科素肺炎菌株. 这一发现强调了抗生素耐药性的全球紧急威胁,以及需要新的治疗策略.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 临床医学 临床医学
背景情况:
- 肺炎链球菌 (Streptococcus pneumoniae) 引起侵袭性肺炎球菌疾病,特别是在儿童中.
- 抗生素对于治疗细菌感染至关重要,但抗生素耐药性是一个日益严重的全球健康危机.
- 伊拉克以前没有报告S. pneumoniae对万科米辛的耐药性.
研究的目的:
- 在伊拉克报告了第一例文献证明的抗万科胺素耐药性肺炎链球菌病例.
- 突出儿童感染中抗菌素耐药性日益增长的挑战.
主要方法:
- 一个怀疑患有脑膜炎的9个月大的婴儿的临床病例呈现.
- 脑脊液 (CSF) 参数的分析:外观,细胞数,蛋白质和葡萄糖水平.
- 通过培养和抗生素敏感性测试来识别肺炎链球菌.
主要成果:
- 婴儿出现了脑膜炎的症状,包括发烧和易怒.
- 脊髓液分析显示了细菌性脑膜炎的特征性迹象.
- 培养物鉴定了肺炎链球菌 (Streptococcus pneumoniae),表现出对菌素的耐药性.
结论:
- 这一案例代表了伊拉克第一个报告中Streptococcus pneumoniae中万科胺耐药性的报告.
- 旺科米辛耐药性的出现强调了全球抗菌素耐药性流行病的不断升级.
- 迫切需要有效的战略来打击不可治疗的感染的威胁.
更多相关视频
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
15.2K
08:53Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
Published on: October 2, 2017
30.4K
相关概念视频
01:30Development of Antibiotic Resistance
219
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
219
01:28Antimicrobial Effectiveness
172
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
172
01:28Pneumonia IV: Management
455
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
455
01:30Pneumonia III: Complications and Assessment
452
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
452
01:29Pneumonia II: Pathophysiology
594
The pathophysiology of pneumonia involves the following steps:
594
01:30Pneumonia I: Introduction
342
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
342